drugset
drugset / Trial / NCT00757029

Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

NCT00757029 ↗

Phase 4 Completed 150 enrolled Hallym University Medical Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.

Timeline

Start
2005-10
Primary completion
2008-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 18 mg —
Subject Methylphenidate Small molecule 54 mg —

Indications

attention deficit-hyperactivity disorder